首頁 › 非小細胞肺癌 › 德克薩斯州 › League City
League City, TX 的 非小細胞肺癌 臨床試驗
15 項針對 非小細胞肺癌 的研究正在 League City（約 30 英里範圍內）及其周邊地點尋找參與者。開啟研究以查看參與資格及聯絡研究團隊的方式。
官方研究文本（英文）
正在為研究招募對象嗎？將此頁面置頂展示 — $99 / 30 天 →
A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
招募中1 期
- The University of Texas, MD Anderson Cancer Center - League City, League City
A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)
招募中3 期
- University Of Texas Medical Branch At Galveston, Galveston · 距離 23 英里
A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
招募中3 期
- The University of Texas, MD Anderson Cancer Center - League City, League City
- Texas Oncology - Gulf Coast, Webster · 距離 3 英里
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
招募中3 期
- Kelsey-Seybold Clinic - Bay Area Campus Building A, Webster · 距離 3 英里
- Kelsey-Seybold Clinic - Bay Area Campus Building B, Webster · 距離 3 英里
- Kelsey-Seybold Clinic - Bay Area Campus Building C, Webster · 距離 3 英里
- 還有 1 項
A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
招募中2 期
- Texas Oncology-Gulf Coast, Webster · 距離 3 英里
Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors
招募中1 期
- Research Site, Galveston · 距離 23 英里
A Study to Investigate Ubamatamab With and Without Marlotamig (REGN7075) in Adult Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
招募中2 期
- University of Texas Medical Branch, Galveston · 距離 23 英里
This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
招募中3 期
- The University of Texas, MD Anderson Cancer Center - League City, League City
A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
招募中3 期
- Local Institution - 0692, Galveston · 距離 23 英里
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
招募中3 期
- Clinical Study Site, Webster · 距離 3 英里
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
招募中3 期
- USO - Texas Oncology, Webster · 距離 3 英里
Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer
招募中3 期
- Research Site, Webster · 距離 3 英里
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
招募中1 期
- Tranquil Clinical Research, Webster · 距離 3 英里
Study of PF-07248144 in Advanced or Metastatic Solid Tumors
招募中2 期
- MD Anderson League City, League City
PILOT for The Precision Exercise Regimen for Cancer Care (PERCC) Study
招募中
- University of Texas Medical Branch at Galveston, Galveston · 距離 23 英里
其他城市的 非小細胞肺癌 試驗
- Houston, TX145 項研究
- New York City, NY121 項研究
- Arlington, VA104 項研究
- Nashville, TN97 項研究
- Boston, MA90 項研究
- Los Angeles, CA87 項研究
- St. Louis, MO73 項研究
- Chicago, IL61 項研究
- Baltimore, MD60 項研究
- San Antonio, TX59 項研究
- Columbus, OH57 項研究
- Washington, DC55 項研究
League City 的其他研究
- 乳癌12 項研究
- 轉移性癌症7 項研究
- 潰瘍性結腸炎6 項研究
- 肺癌6 項研究
- 大腸直腸癌6 項研究
- 癌症（所有類型）5 項研究
- 卵巢癌5 項研究
- 中風5 項研究
- 膀胱癌4 項研究
- 頭頸部鱗狀細胞癌4 項研究
- 前列腺癌4 項研究
- COVID-19 後遺症（長新冠）3 項研究
資料來源：ClinicalTrials.gov，擷取日期 2026年10月6日。各研究自行設定資格標準；由研究團隊決定參與者資格。